Physician profile
Michael Ryan Chambers
NPI 1194259523
$622.97
in general payments reported to CMS, 2019-2025
11 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $134 · 2024: $185 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $162.83 | 2023-2025 | Dovato, Cabenuva, Apretude |
| Melinta Therapeutics, LLC | $96.89 | 2025 | Rezzayo |
| Abbvie INC. | $91.03 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $75.52 | 2023-2025 | Dificid, Pifeltro, Delstrigo |
| La Jolla Pharmaceutical Company | $54.36 | 2025 | Zevtera |
| Gilead Sciences, INC. | $29.88 | 2023-2024 | |
| Insmed, INC. | $27.29 | 2024 | Arikayce |
| Tersera Therapeutics LLC | $25.79 | 2024 | Quzyttir |
| Cumberland Pharmaceuticals, INC. | $21.18 | 2025 | Vibativ |
| Octapharma USA, INC. | $20.64 | 2023 | Octagam Immune Globulin (Human) |
| Amgen INC. | $17.56 | 2024 | Evenity, Prolia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chambers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.